
The first peer-reviewed EASYGEN consortium perspective examines the barriers limiting CAR-T access in Europe and the potential role of decentralised manufacturing, automation and non-viral gene engineering in addressing them.
The article is available online ahead of its September 2026 issue publication in Cytotherapy.





